In Re: Namenda Direct Purchaser Antitrust Litigation

Dr. Russell Lamb was retained on behalf of a proposed class of direct purchasers of branded and generic Namenda tablets in a class action involving allegations of anticompetitive pay-for-delay and hard-switch conduct. In its Memorandum Decision and Order granting Plaintiffs’ motion for class certification, the Court noted that “Dr. Lamb independently reviewed and analyzed Forest’s internal document[s] and testimony” as part of his analysis of the but-for world,” which the Court held to be a “sound economic methodology.”